Your browser doesn't support javascript.
loading
Dimeric IgA specifically disables intracellular mutated oncodrivers.
Prince, Stuart; Hollmén, Maija.
Affiliation
  • Prince S; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
  • Hollmén M; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland. Electronic address: maijal@utu.fi.
Immunity ; 56(11): 2461-2463, 2023 Nov 14.
Article in En | MEDLINE | ID: mdl-37967526
ABSTRACT
A prevailing belief in the immunotherapy field has been that antibody therapy can effectively target only extracellular antigens. In this issue of Immunity, Biswas et al. demonstrate therapeutically effective targeting, neutralization, and removal of mutated oncodriver proteins from within epithelial cancer cells by treatment with pIgR-dependent, transcytosing dimeric-IgA antibodies.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin A / Antigens Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2023 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin A / Antigens Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2023 Document type: Article Affiliation country: